» Articles » PMID: 26292663

Knockdown of NAT12/NAA30 Reduces Tumorigenic Features of Glioblastoma-initiating Cells

Overview
Journal Mol Cancer
Publisher Biomed Central
Date 2015 Aug 22
PMID 26292663
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Glioblastoma (GBM) is the most common primary brain malignancy and confers a dismal prognosis. GBMs harbor glioblastoma-initiating cells (GICs) that drive tumorigenesis and contribute to therapeutic resistance and tumor recurrence. Consequently, there is a strong rationale to target this cell population in order to develop new molecular therapies against GBM. Accumulating evidence indicates that Nα-terminal acetyltransferases (NATs), that are dysregulated in numerous human cancers, can serve as therapeutic targets.

Methods: Microarrays were used to study the expression of several NATs including NAT12/NAA30 in clinical samples and stem cell cultures. The expression of NAT12/NAA30 was analyzed using qPCR, immunolabeling and western blot. We conducted shRNA-mediated knockdown of NAT12/NAA30 gene in GICs and studied the effects on cell viability, sphere-formation and hypoxia sensitivity. Intracranial transplantation to SCID mice enabled us to investigate the effects of NAT12/NAA30 depletion in vivo. Using microarrays we identified genes and biochemical pathways whose expression was altered upon NAT12/NAA30 down-regulation.

Results: While decreased expression of the distal 3'UTR of NAT12/NAA30 was generally observed in GICs and GBMs, this gene was strongly up-regulated at the protein level in GBM and GICs. The increased protein levels were not caused by increased levels of the steady state mRNA but rather by other mechanisms. Also, shorter 3'UTR of NAT12/NAA30 correlated with poor survival in glioma patients. As well, we observed previously not described nuclear localization of this typically cytoplasmic protein. When compared to non-silencing controls, cells featuring NAT12/NAA30 knockdown exhibited reduced cell viability, sphere-forming ability, and mitochondrial hypoxia tolerance. Intracranial transplantation showed that knockdown of NAT12/NAA30 resulted in prolonged animal survival. Microarray analysis of the knockdown cultures showed reduced levels of HIF1α and altered expression of several other genes involved in the hypoxia response. Furthermore, NAT12/NAA30 knockdown correlated with expressional dysregulation of genes involved in the p53 pathway, ribosomal assembly and cell proliferation. Western blot analysis revealed reduction of HIF1α, phospho-MTOR(Ser2448) and higher levels of p53 and GFAP in these cultures.

Conclusion: NAT12/NAA30 plays an important role in growth and survival of GICs possibly by regulating hypoxia response (HIF1α), levels of p-MTOR (Ser2448) and the p53 pathway.

Citing Articles

Illuminating the impact of N-terminal acetylation: from protein to physiology.

McTiernan N, Kjosas I, Arnesen T Nat Commun. 2025; 16(1):703.

PMID: 39814713 PMC: 11735805. DOI: 10.1038/s41467-025-55960-5.


Exploring the role of N-acetyltransferases in diseases: a focus on N-acetyltransferase 9 in neurodegeneration.

Deshpande P, Chimata A, Singh A Neural Regen Res. 2024; 20(10):2862-2871.

PMID: 39435604 PMC: 11826463. DOI: 10.4103/NRR.NRR-D-24-00779.


ATP6V1D drives hepatocellular carcinoma stemness and progression via both lysosome acidification-dependent and -independent mechanisms.

Xu Z, Liu R, Ke H, Xu F, Yang P, Zhang W Autophagy. 2024; 21(3):513-529.

PMID: 39316516 PMC: 11849949. DOI: 10.1080/15548627.2024.2406186.


Bioinformatic Analysis Reveals the Association of Human N-Terminal Acetyltransferase Complexes with Distinct Transcriptional and Post-Transcriptional Processes.

Koufaris C, Demetriadou C, Nicolaidou V, Kirmizis A Biochem Genet. 2024; .

PMID: 38864963 DOI: 10.1007/s10528-024-10860-z.


N-terminal acetylation shields proteins from degradation and promotes age-dependent motility and longevity.

Varland S, Silva R, Kjosas I, Faustino A, Bogaert A, Billmann M Nat Commun. 2023; 14(1):6774.

PMID: 37891180 PMC: 10611716. DOI: 10.1038/s41467-023-42342-y.


References
1.
Chen J, Li Y, Yu T, McKay R, Burns D, Kernie S . A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012; 488(7412):522-6. PMC: 3427400. DOI: 10.1038/nature11287. View

2.
Suva M, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle J . EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res. 2009; 69(24):9211-8. DOI: 10.1158/0008-5472.CAN-09-1622. View

3.
Vik-Mo E, Sandberg C, Olstorn H, Varghese M, Brandal P, Ramm-Pettersen J . Brain tumor stem cells maintain overall phenotype and tumorigenicity after in vitro culturing in serum-free conditions. Neuro Oncol. 2010; 12(12):1220-30. PMC: 3018941. DOI: 10.1093/neuonc/noq102. View

4.
Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S . Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 2009; 15(6):501-13. PMC: 2693960. DOI: 10.1016/j.ccr.2009.03.018. View

5.
Lutz C . Alternative polyadenylation: a twist on mRNA 3' end formation. ACS Chem Biol. 2008; 3(10):609-17. DOI: 10.1021/cb800138w. View